Drug
Hmpl 453
Hmpl 453: highest development phase Phase 2, developed by Hutchmed, United Therapeutics. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Hutchmed, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| HMPL-453 NCT04290325 | Phase 2 | Advanced Malignant Mesothelioma |
| HMPL-453 NCT07644442 | Phase 1 | Mass Balance Study |
| HMPL-453 NCT05930119 | Phase 1 | Intrahepatic Cholangiocarcinoma |
Latest
No recent events.
Follow Hmpl 453 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.